Biomarker Endostatin Linked To Kidney Function Decline in Diabetes Interview with:
Axel C. Carlsson, PhD
Department of Medical Sciences, Molecular Epidemiology and Science for Life Laboratory, Uppsala University
Uppsala Sweden What is the background for this study?

Dr. Carlsson: Circulating endostatin levels has been shown to be associated with duration of hypertension and cardiovascular events. Moreover, endostatin levels were recently shown to parallel kidney function decline, and has been associated with increased mortality risk in different settings. However, less is known of circulating endostatin in patients with type 2 diabetes. What are the main findings?

Dr. Carlsson: Higher levels of endostatin were cross-sectionally associated with nephropathy.

In longitudinal analyses, higher levels of endostatin predicted a more rapid decline in kidney function, and an increased mortality risk independently of baseline kidney function, albuminuria and glucose control. What should clinicians and patients take away from your report?

Dr. Carlsson: In the last decades there has been little advancement in the discovery of clinically relevant risk markers that could be used for prognostic purposes in the routine clinical care of the diabetes patients. In the present study, endostatin clearly predicted adverse outcomes independently of both eGFR and ACR. Endostatin may, after further study prove to be a relevant marker of increased risk of adverse events in patients with diabetes. What recommendations do you have for future research as a result of this study?

Dr. Carlsson: Further studies are warranted to elucidate the utility of measuring endostatin to monitor kidney function decline and associated risks in clinical practice.


The association between endostatin and kidney disease and mortality in patients with type 2 diabetes

Carlsson A.C.a, b · Carrero J.-J.c · Stenvinkel P.c · Bottai M.d · Barany P.c · Larsson A.e · Ärnlöv J.b, f Blood Purification  Vol. 39, No. 4, 2015 Issue release date: June 2015

[wysija_form id=”5″]





Last Updated on April 17, 2016 by Marie Benz MD FAAD